PartnershipJun 3, 2026, 08:32 AM
Alpha Tau Medical Partners with Tolmar for Alpha DaRT; $20M Equity
AI Summary
Alpha Tau Medical Ltd. announced a strategic collaboration and supply agreement with Tolmar International Ltd., granting Tolmar exclusive U.S. commercialization rights for Alpha DaRT for prostate cancer. The agreement includes an initial $15.0 million payment for manufacturing expansion and up to $161.5 million in milestone payments. Concurrently, Alpha Tau entered a private placement with Tolmar, selling 1,668,057 ordinary shares at a 25% premium for $20.0 million in gross proceeds, intended for general corporate purposes. Tolmar also holds an option to expand into bladder cancer, subject to additional payments and a further securities purchase.
Key Highlights
- Alpha Tau granted Tolmar exclusive U.S. commercialization rights for Alpha DaRT for prostate cancer.
- Tolmar will make an initial $15.0 million payment for manufacturing expansion.
- Alpha Tau is eligible for up to $161.5 million in clinical, regulatory, and commercial milestone payments.
- Alpha Tau will supply Alpha DaRT to Tolmar at 60% of net sales.
- Tolmar has an option to expand into bladder cancer, subject to additional payments.
- Alpha Tau entered a private placement with Tolmar for 1,668,057 ordinary shares at $11.99 per share.
- The private placement is expected to generate gross proceeds of $20.0 million for Alpha Tau.
- Tolmar will purchase an additional $5.0 million in shares if the bladder cancer option is exercised.
Price Impact
More from DRTS